Ligand Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is June - May.

Millions CAD. Fiscal year is Jun - May.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '25 Feb 28, 2025	May '24 May 31, 2024	May '23 May 31, 2023	May '22 May 31, 2022	May '21 May 31, 2021	May '20 May 31, 2020
Selling, General & Admin	0.86	0.9	0.94	1.36	1.33	0.14
Research & Development	0.52	2.14	3.02	2.61	0.75	-
Operating Expenses	1.38	3.04	3.96	3.96	2.43	0.14
Operating Income	-1.38	-3.04	-3.96	-3.96	-2.43	-0.14
Interest & Investment Income	0.08	0.19	0.21	-	-	-
Earnings From Equity Investments	-0.03	-0.05	-	-	-	-
Other Non Operating Income (Expenses)	-0.05	-0.04	-0.03	-0.14	-0.39	-
EBT Excluding Unusual Items	-1.38	-2.95	-3.78	-4.1	-2.82	-0.14
Gain (Loss) on Sale of Investments	-0.1	-0.17	-2.63	-0.13	-0.9	-
Gain (Loss) on Sale of Assets	-	-	-	-	7	-
Other Unusual Items	-	-	-	-	-0.39	-
Pretax Income	-1.48	-3.12	-6.42	-4.24	2.89	-0.14
Income Tax Expense	-	-	-	-0.23	0.23	-
Net Income	-1.48	-3.12	-6.42	-4.01	2.66	-0.14
Net Income to Common	-1.48	-3.12	-6.42	-4.01	2.66	-0.14
Shares Outstanding (Basic)	88	88	88	81	65	34
Shares Outstanding (Diluted)	88	88	88	81	73	34
Shares Change (YoY)	0.36%	0.07%	8.71%	10.70%	114.98%	-
EPS (Basic)	-0.02	-0.04	-0.07	-0.05	0.04	-
EPS (Diluted)	-0.02	-0.04	-0.07	-0.05	0.04	-
Free Cash Flow	-1.24	-3.52	-3.24	-3.51	0.92	-0
Free Cash Flow Per Share	-0.01	-0.04	-0.04	-0.04	0.01	-
EBITDA	-1.38	-3.04	-3.96	-3.96	-2.43	-
D&A For EBITDA	0	0	0	0	0	-
EBIT	-1.38	-3.04	-3.96	-3.96	-2.43	-0.14
Effective Tax Rate	-	-	-	-	7.79%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.